Yonsei Med J.  2013 Nov;54(6):1384-1393. 10.3349/ymj.2013.54.6.1384.

Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on the Risk of Lung Cancer and the Clinical Response to Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer: An Updated Meta-Analysis

Affiliations
  • 1Department of Respiratory Diseases, Huashan Hospital, Fudan University, Shanghai, China. xdchen8@hotmail.com

Abstract

PURPOSE
Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). However, the results are controversial. We performed meta-analysis to investigate the effect of MTHFR C677T polymorphism on lung cancer risk and response to platinum-based chemotherapy in advanced NSCLC.
MATERIALS AND METHODS
The databases of PubMed, Ovid, Wanfang and Chinese Biomedicine were searched for eligible studies. Nineteen studies on MTHFR C677T polymorphism and lung cancer risk and three articles on C677T polymorphism and response to platinum-based chemotherapy in advanced NSCLC, were identified.
RESULTS
The results indicated that the allelic contrast, homozygous contrast and recessive model of the MTHFR C677T polymorphism were associated significantly with increased lung cancer risk. In the subgroup analysis, the C677T polymorphism was significantly correlated with an increased risk of NSCLC, with the exception of the recessive model. The dominant model and the variant T allele showed a significant association with lung cancer susceptibility of ever smokers. Male TT homozygote carriers had a higher susceptibility, but the allelic contrast and homozygote model had a protective effect in females. No relationship was observed for SCLC in any comparison model. In addition, MTHFR 677TT homozygote carriers had a better response to platinum-based chemotherapy in advanced NSCLC in the recessive model.
CONCLUSION
The MTHFR C677T polymorphism might be a genetic marker for lung cancer risk or response to platinum-based chemotherapy in advanced NSCLC. However, our results require further verification.

Keyword

MTHFR; C677T; polymorphism; lung cancer; platinum-based chemotherapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics
Genetic Predisposition to Disease
Humans
Lung Neoplasms/drug therapy/*enzymology/*genetics
Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
Platinum/*therapeutic use
Polymorphism, Genetic/genetics
Methylenetetrahydrofolate Reductase (NADPH2)
Platinum

Figure

  • Fig. 1 Flow chart of the reterived steps of our meta-analysis. NSCLC, non-small cell lung cancer; CBM, Chinese Biomedicine.

  • Fig. 2 Meta-analysis for the association between the recessive model of MTHFR C677T polymorphism and response to platinum-based chemotherapy in advanced NSCLC. CI, confidence interval; NSCLC, non-small cell lung cancer.

  • Fig. 3 Funnel plot of MTHFR C677T ploymorphism and lung cancer (T allele vs. C allele).


Reference

1. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003; 3:912–920.
Article
2. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004; 208:1–33.
Article
3. Vaissière T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009; 69:243–252.
Article
4. Männistö S, Smith-Warner SA, Spiegelman D, Albanes D, Anderson K, van den Brandt PA, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev. 2004; 13:40–48.
Article
5. Jatoi A, Daly BD, Kramer G, Mason JB. Folate status among patients with non-small cell lung cancer: a case-control study. J Surg Oncol. 2001; 77:247–252.
Article
6. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem. 1999; 10:66–88.
Article
7. Voorrips LE, Goldbohm RA, Brants HA, van Poppel GA, Sturmans F, Hermus RJ, et al. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000; 9:357–365.
8. Shimamoto T, Ohyashiki JH, Hirano T, Kato H, Ohyashiki K. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. Oncol Rep. 2004; 12:389–395.
Article
9. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 2004; 96:134–144.
Article
10. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 2001; 10:397–401.
11. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 2005; 5:226–243.
Article
12. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y. Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population. BMC Cancer. 2011; 11:459.
Article
13. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, Choi JS. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics. 2011; 12:797–808.
Article
14. Siemianowicz K, Gminski J, Garczorz W, Slabiak N, Goss M, Machalski M, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep. 2003; 10:1341–1344.
Article
15. Suzuki T, Matsuo K, Hiraki A, Saito T, Sato S, Yatabe Y, et al. Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis. 2007; 28:1718–1725.
Article
16. Liu CS, Tsai CW, Hsia TC, Wang RF, Liu CJ, Hang LW, et al. Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. Cancer Genomics Proteomics. 2009; 6:325–329.
17. Zhang Y, Chen GQ, Ji Y, Huang B, Shen WS, Deng LC, et al. Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma. Mol Biol Rep. 2012; 39:6203–6211.
Article
18. Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-reated stage IV non-small-cell lung cancer. Clin Lung Cancer. 2004; 5:360–365.
Article
19. Shi M, Gao C, Wu J, Feng J, Cao H, Lu J, et al. [Genetic polymorphisms in methylenetetrahydrofolate reductase and clinical response to chemotherapy in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2006; 9:519–524.
20. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005; 28:123–137.
Article
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–1558.
Article
22. Takehara A, Kawakami K, Ohta N, Oyama K, Ota Y, Oda M, et al. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res. 2005; 25:4455–4461.
23. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol. 2007; 18:1230–1242.
Article
24. Zhou QF, Chen SQ, Ma L, Li ZB, Li WD, Chen WS, et al. The associations of MTHFR polymorphism and lung cancer risk (chinese). Chin J Cancer Res Prev Treat. 2006; 8:572–574.
25. Jin C, Zhang YH, Peng MF, Li WD, Ma L, Chen WS. The association between MTHFR polymorphism and lung cancer (chinese). Chin J Cancer Prev Treat. 2007; 12:888–891.
26. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006; 17:668–675.
Article
27. Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, et al. Prognostic significance of folate metabolism polymorphisms for lung cancer. Br J Cancer. 2007; 97:247–252.
Article
28. Heijmans BT, Boer JM, Suchiman HE, Cornelisse CJ, Westendorp RG, Kromhout D, et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res. 2003; 63:1249–1253.
29. Jeng YL, Wu MH, Huang HB, Lin WY, You SL, Chu TY, et al. The methylenetetrahydrofolate reductase 677C-->T polymorphism and lung cancer risk in a Chinese population. Anticancer Res. 2003; 23:5149–5152.
30. Shen M, Rothman N, Berndt SI, He X, Yeager M, Welch R, et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer. 2005; 49:299–309.
Article
31. Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, et al. Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev. 2005; 14:1477–1484.
Article
32. Zhang XM, Miao XP, Tan W, Qu SN, Sun T, Zhou YF, et al. [Association between genetic polymorphisms in methylentetrahydrofolate reductase and risk of lung cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005; 27:700–703.
33. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007; 28:1287–1293.
Article
34. Hung RJ, Hashibe M, McKay J, Gaborieau V, Szeszenia-Dabrowska N, Zaridze D, et al. Folate-related genes and the risk of tobacco-related cancers in Central Europe. Carcinogenesis. 2007; 28:1334–1340.
Article
35. Liu H, Jin G, Wang H, Wu W, Liu Y, Qian J, et al. Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. Lung Cancer. 2008; 61:21–29.
Article
36. Arslan S, Karadayi S, Yildirim ME, Ozdemir O, Akkurt I. The association between methylene-tetrahydrofolate reductase gene polymorphism and lung cancer risk. Mol Biol Rep. 2011; 38:991–996.
Article
37. Cui LH, Shin MH, Kim HN, Song HR, Piao JM, Kweon SS, et al. Methylenetetrahydrofolate reductase C677T polymorphism in patients with lung cancer in a Korean population. BMC Med Genet. 2011; 12:28.
Article
38. Cheng Z, Wang W, Song YN, Xia J, Kang Y, Dai LL, et al. The relationship between MTHFR C677T polymorphism and lung cancer risk (chinese). Chin J Tuberc Respir Dis. 2011; 34:57–58.
39. Jin C, Zhang YH, Peng MF, Li WD, Ma L, Chen WS. The relationship between MTHFR C677T and A1298C polymorphism and lung cancer risk (chinese). Lin Chuang Zhong Liu Xue Za Zhi. 2007; 9:671–675.
40. Yang XX, Li FX, Yi JP, Li X, Sun JZ, Hu NY. The relationship between MTHFR C677T polymorphism and gastric cancer, colon cancer or lung cancer risk (chinese). Guangdong Med J. 2010; 31:2375–2378.
41. Tong SY, Kim MK, Lee JK, Lee JM, Choi SW, Friso S, et al. Common polymorphisms in methylenetetrahydrofolate reductase gene are associated with risks of cervical intraepithelial neoplasia and cervical cancer in women with low serum folate and vitamin B12. Cancer Causes Control. 2011; 22:63–72.
Article
42. Xuan C, Bai XY, Gao G, Yang Q, He GW. Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: a meta-analysis for 8,140 cases and 10,522 controls. Arch Med Res. 2011; 42:677–685.
Article
43. Yan J, Yin M, Dreyer ZE, Scheurer ME, Kamdar K, Wei Q, et al. A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer. 2012; 58:513–518.
Article
44. Jokić M, Brčić-Kostić K, Stefulj J, Catela Ivković T, Božo L, Gamulin M, et al. Association of MTHFR, MTR, MTRR, RFC1, and DHFR gene polymorphisms with susceptibility to sporadic colon cancer. DNA Cell Biol. 2011; 30:771–776.
Article
45. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. J Hum Genet. 2008; 53:340–348.
Article
46. Boccia S, Boffetta P, Brennan P, Ricciardi G, Gianfagna F, Matsuo K, et al. Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett. 2009; 273:55–61.
Article
47. Hou XH, Huang YM, Mi YY. Methylenetetrahydrofolate reductase gene C677T polymorphism and lung cancer: an updated meta-analysis. Asian Pac J Cancer Prev. 2012; 13:2025–2029.
Article
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr